(S)-pentan-2-yl 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate → HCID 178448290, Verbindung

HRID 245760Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 245760
[CH3:1][O:2][C:3]1[CH:8]=[C:7](B2OC(C)(C)C(C)(C)O2)[CH:6]=[CH:5][C:4]=1[NH:18][C:19](=[O:26])[O:20][C@H:21]([CH2:23][CH2:24][CH3:25])[CH3:22].Br[C:28]1[N:29]=[C:30]([C@H:38]2[CH2:43][CH2:42][C@H:41]([CH2:44][NH:45][C:46](=[O:48])[CH3:47])[CH2:40][CH2:39]2)[N:31]2[CH:36]=[CH:35][N:34]=[C:33]([CH3:37])[C:32]=12>>[C:46]([NH:45][CH2:44][C@H:41]1[CH2:40][CH2:39][C@H:38]([C:30]2[N:31]3[CH:36]=[CH:35][N:34]=[C:33]([CH3:37])[C:32]3=[C:28]([C:7]3[CH:6]=[CH:5][C:4]([NH:18][C:19](=[O:26])[O:20][C@H:21]([CH2:23][CH2:24][CH3:25])[CH3:22])=[C:3]([O:2][CH3:1])[CH:8]=3)[N:29]=2)[CH2:43][CH2:42]1)(=[O:48])[CH3:47]

Komponenten

3

Versuchsvorschrift

(S)-Pentan-2-yl 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl-carbamate (20 mg) and N-(((trans)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)cyclohexyl)methyl)acetamide (20 mg) were reacted according to the procedure described in example 4 step 4c and purified by prep-HPLC (column Luna C18(2); gradient acetonitrile/water with constant 0.003M trifluoroacetic acid). Proper fractions were collected and made basic with aqueous sodium hydrogencarbonate, extracted with dichloromethane, organic layer dried (Na2SO4) and concentrated in vacuo to give (S)-pentan-2-yl 4-(3-((trans)-4-(acetamidomethyl)cyclohexyl)-8-methylimidazo[1,5-a]pyrazin-1-yl)-2-methoxyphenylcarbamate (16 mg).

Aufarbeitung

  1. custompurified by prep-HPLC (column Luna C18(2); gradient acetonitrile/water with constant 0.003M trifluoroacetic acid)
  2. customProper fractions were collected
  3. extractionextracted with dichloromethane, organic layer
  4. dry with materialdried (Na2SO4)
  5. concentrationconcentrated in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-5d87fcf60460465b9962508217c4528b
Quelldatensatz
uspto-grants-2014_02
Patentnummer
US08658794B2

Notizen zur Reaktion

Wird geladen…